Glaukos Corp. Reports Q4 Loss, Tops Expectations
ALISO VIEJO, Calif. - Glaukos Corp. (GKOS) announced a net loss of $33.6 million in its fourth quarter, translating to a per-share loss of 60 cents.
Excluding non-recurring expenses, the loss was 40 cents per share, exceeding analysts' consensus estimate of 43 cents.
Revenue for the period reached $105.5 million, also surpassing market expectations. Analysts had projected revenue of $100.8 million.
The glaucoma treatments developer expects full-year revenue in the range of $475 million to $485 million.